H.C. Wainwright raised the firm’s price target on Janux Therapeutics to $50 from $35 and keeps a Buy rating on the shares following the Q4 report. The analyst believes the company’s cash is sufficient to run operations for the foreseeable future.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on JANX:
